ASX June Health Winners: Sector falls 1.05pc but Amplia up 300pc after positive trial news
Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY
Amplia up 300% in June after complete responses in two advanced (metastatic) pancreatic cancer patients in ACCENT trial
While the broader market showed resilience to global geopolitical and economic pressures in June, the ASX 200 Health Care index remained in poor shape, falling 1.05% for the month.
The sector remains the worst-performing ASX sector year-to-date and the only one in the red, down 6.64%.
Morgans healthcare analyst Iain Wilkie told Stockhead the first half of 2025 had been highly volatile for the global healthcare sector, driven by policy uncertainty in the US.
He said Donald Trump's policies were impacting the sector including funding cuts and shakeups to regulatory agencies such as the US Food and Drug Administration (FDA).
In addition, Trump is advancing the 'Most Favored Nation' (MFN) drug pricing policy, which seeks to align US prescription medicine prices with the lowest levels paid in other developed nations.
While the policy's full implementation remains pending, it has already created uncertainty for pharmaceutical companies, with no clear path yet on how it will be enforced or the potential market ramifications.
Wilkie said the sector likely also saw some tax loss selling in June – the final month of the Australian financial year – with many investors crystallising losses in this space to offset gains made in other parts of their portfolios.
"We often view this month as a potential opportunity to stock up on some companies at a discount if we continue to see long term value in them and approaching significant catalysts," he said.
How ASX biotechs performed in June
CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP
ATX Amplia Therapeutics 20 300.0% 91.17
NSB Neuroscientific 8.7 50.0% 36.58
OSL Oncosil Medical 120 50.0% 17.06
EZZ EZZ Life Science 234 49.5% 116.05
NYR Nyrada Inc. 24 45.5% 50.62
CGS Cogstate Ltd 174.5 33.7% 295.62
ALA Arovella Therapeutic 10 31.6% 112.91
AHX Apiam Animal Health 52 28.4% 92.89
PEB Pacific Edge 9.6 28.0% 81.19
IRX Inhalerx Limited 3.8 26.7% 7.90
NC6 Nanollose Limited 6.7 26.4% 20.74
VLS Vita Life Sciences 225 23.6% 123.28
SHG Singular Health 37 21.3% 120.68
CSX Cleanspace Holdings 52 20.9% 39.89
IPD Impedimed Limited 3.5 16.7% 79.07
ALC Alcidion Group Ltd 10 16.3% 147.72
IVX Invion Ltd 11 15.8% 8.49
CU6 Clarity Pharma 250 15.7% 763.53
NUZ Neurizon Therapeutic 15.5 14.8% 76.31
ARX Aroa Biosurgery 58 13.7% 193.22
SOM SomnoMed Limited 65 11.1% 138.31
COH Cochlear Limited 30042 10.7% 19,917.31
CTQ Careteq Limited 1.1 10.0% 2.61
ACW Actinogen Medical 2.3 9.5% 73.07
EBR EBR Systems 119.5 7.7% 523.20
DVL Dorsavi Ltd 1.5 7.1% 12.62
PYC PYC Therapeutics 129.5 7.0% 755.32
COV Cleo Diagnostics 39 6.8% 31.82
OCA Oceania Healthc Ltd 63 6.8% 456.27
CMB Cambium Bio Limited 21 5.0% 3.84
IDX Integral Diagnostics 254 5.0% 904.56
RMD ResMed Inc. 3935 3.8% 23,160.79
EMD Emyria Limited 2.8 3.7% 16.51
EBO Ebos Group Ltd 3559 3.5% 1,919.95
TRP Tissue Repair 19 2.7% 11.19
EMV Emvision Medical 174 2.4% 149.23
SNZ Summerset Grp Hldgs 1044 2.3% 2,414.13
NEU Neuren Pharmaceut. 1411 1.7% 1,811.96
SPL Starpharma Holdings 8.8 1.1% 36.39
PME Pro Medicus Limited 28508 1.1% 15,301.07
MYX Mayne Pharma Ltd 500 1.0% 381.86
SHL Sonic Healthcare 2679 0.4% 12,836.39
1AD Adalta Limited 0.2 0.0% 2.14
AGH Althea Group 2.5 0.0% 20.56
ANR Anatara Ls Ltd 0.5 0.0% 1.07
CHM Chimeric Therapeutic 0.4 0.0% 9.07
DOC Doctor Care Anywhere 10.5 0.0% 42.16
DXB Dimerix Ltd 57.5 0.0% 346.85
EOF Ecofibre Limited 2 0.0% 7.58
EPN Epsilon Healthcare 2.4 0.0% 8.29
ICR Intelicare Holdings 0.7 0.0% 2.92
MEM Memphasys Ltd 0.5 0.0% 8.93
TD1 Tali Digital Limited 0.1 0.0% 4.10
CTE Cryosite Limited 74.5 -0.7% 36.36
FPH Fisher & Paykel H. 3363 -0.9% 6,557.10
SDI SDI Limited 83 -2.4% 97.47
ACL Au Clinical Labs 278 -2.5% 388.89
MSB Mesoblast Limited 165.5 -2.6% 1,810.36
NXS Next Science Limited 6.7 -2.9% 32.14
CSL CSL Limited 23948 -3.0% 115,358.67
AHC Austco Healthcare 29 -3.3% 107.40
CBL Control Bionics 2.9 -3.3% 9.43
LDX Lumos Diagnostics 2.7 -3.6% 19.46
CUV Clinuvel Pharmaceut. 1038 -3.7% 451.46
REG Regis Healthcare Ltd 784 -3.8% 1,167.64
ANN Ansell Limited 3029 -4.0% 4,490.73
SIG Sigma Health Ltd 299 -4.2% 17,142.40
RHC Ramsay Health Care 3669 -4.2% 7,017.07
IXC Invex Ther 8.9 -4.3% 6.69
PTX Prescient Ltd 4.4 -4.3% 33.02
PAR Paradigm Bio. 30.5 -4.7% 146.04
OCC Orthocell Limited 117.5 -5.2% 305.40
AYA Artryalimited 72 -5.3% 79.35
AVR Anteris Technologies 614 -5.5% 92.84
ONE Oneview Healthcare 25 -5.7% 190.96
FRE Firebrickpharma 6.2 -6.1% 14.37
AGN Argenica 76 -6.2% 95.43
TYP Tryptamine Ltd 3 -6.3% 43.06
TLX Telix Pharmaceutical 2442 -6.4% 7,003.27
AFP Aft Pharmaceuticals 243 -6.5% 254.83
CDX Cardiex Limited 4 -7.0% 22.00
PGC Paragon Care Limited 36.5 -7.6% 620.74
AVH Avita Medical 171.5 -7.8% 113.37
MVF Monash IVF Group Ltd 70.5 -7.8% 280.54
RAC Race Oncology Ltd 117.5 -8.2% 203.28
1AI Algorae Pharma 0.55 -8.3% 8.44
RAD Radiopharm 2.2 -8.3% 53.21
PNV Polynovo Limited 119.5 -8.8% 829.01
NAN Nanosonics Limited 405 -8.8% 1,155.80
VIT Vitura Health Ltd 6.2 -8.8% 41.72
IMC Immuron Limited 6.1 -9.0% 15.21
ATH Alterity Therap Ltd 1 -9.1% 91.27
PER Percheron 1 -9.1% 10.33
VHL Vitasora Health Ltd 3.9 -9.3% 61.50
TRJ Trajan Group Holding 71.5 -9.5% 111.24
ECS ECS Botanics Holding 0.9 -10.0% 11.66
LGP Little Green Pharma 9.9 -10.0% 33.44
HLS Healius 78.5 -10.3% 544.60
M7T Mach7 Tech Limited 33 -10.8% 82.02
MDR Medadvisor Limited 8.1 -11.0% 53.11
CVB Curvebeam Ai Limited 7.1 -11.3% 23.76
RHT Resonance Health 3.9 -11.4% 18.84
IBX Imagion Biosys Ltd 1.1 -12.0% 2.42
IME Imexhs Limited 29 -12.1% 15.56
BMT Beamtree Holdings 25 -12.3% 69.64
MX1 Micro-X Limited 4.9 -12.5% 32.69
IMR Imricor Med Sys 152 -12.6% 496.69
ZLD Zelira Therapeutics 44 -12.9% 5.23
IMU Imugene Limited 44.2 -13.3% 104.54
LTP Ltr Pharma Limited 29 -13.4% 36.39
BOT Botanix Pharma Ltd 32 -13.5% 605.72
CMP Compumedics Limited 25.5 -13.6% 49.02
GLH Global Health Ltd 6.8 -13.9% 3.92
PSQ Pacific Smiles Grp 154.5 -14.4% 239.20
RGT Argent Biopharma Ltd 8.1 -14.7% 5.77
AT1 Atomo Diagnostics 1.4 -15.2% 10.32
IDT IDT Australia Ltd 8.9 -15.2% 40.82
EYE Nova EYE Medical Ltd 11 -15.4% 32.68
CC5 Clever Culture 1.6 -15.8% 30.03
UCM Uscom Limited 1.6 -15.8% 4.01
IMM Immutep Ltd 24 -15.8% 350.49
IIQ Inoviq Ltd 37 -15.9% 41.30
BDX Bcaldiagnostics 6.3 -16.0% 24.52
MVP Medical Developments 54.5 -16.2% 61.40
CYP Cynata Therapeutics 15 -16.7% 38.41
PCK Painchek Ltd 4.5 -16.7% 73.68
RHY Rhythm Biosciences 5.4 -16.9% 15.34
UBI Universal Biosensors 3.5 -18.6% 10.43
RCE Recce Pharmaceutical 29 -19.4% 82.19
BIT Biotron Limited 0.2 -20.0% 2.65
BP8 Bph Global Ltd 0.2 -20.0% 2.10
SNT Syntara Limited 5.3 -20.9% 82.87
OIL Optiscan Imaging 11 -21.4% 100.24
PIQ Proteomics Int Lab 32.5 -23.5% 59.69
GSS Genetic Signatures 36.5 -24.0% 86.31
CYC Cyclopharm Limited 91 -24.2% 102.25
VFX Visionflex Group Ltd 0.15 -25.0% 6.74
NOX Noxopharm Limited 5.4 -26.0% 15.20
HIQ Hitiq Limited 1.4 -26.3% 6.90
CAN Cann Group Ltd 1 -28.6% 7.00
NTI Neurotech Intl 1.5 -28.6% 18.89
4DX 4Dmedical Limited 24 -29.4% 114.05
AVE Avecho Biotech Ltd 0.35 -30.0% 12.69
ACR Acrux Limited 1.6 -30.4% 7.34
ADR Adherium Ltd 0.4 -33.3% 4.49
PAB Patrys Limited 0.1 -33.3% 2.37
VBS Vectus Biosystems 4 -33.3% 2.02
ILA Island Pharma 14 -37.8% 30.69
TRI Trivarx Ltd 0.8 -38.5% 4.96
OSX Osteopore Limited 1.1 -38.9% 2.20
TRU Truscreen 1.6 -40.7% 11.75
MAP Microbalifesciences 8.5 -45.2% 43.78
HMD Heramed Limited 0.7 -46.2% 9.63
Amplia Therapeutics (ASX:ATX) rose 300% in June after a series of positive announcements including confirmed pathological complete responses recorded in two advanced (metastatic) pancreatic cancer patient as part of its ACCENT trial.
The trial is investigating Amplia's best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane in patients with metastatic pancreatic cancer.
Amplia also announced in June it had received US ethics approval of the protocol for its forthcoming Phase II clinical trial of narmafotinib in combination with the chemotherapy FOLFIRINOX in advanced pancreatic cancer.
NeuroScientific Biopharmaceuticals (ASX:NSB) was up 50% in June after announcing it had acquired 100% of Perth-based unlisted company Isopogen WA, which owns or holds the rights to commercialise the patented StemSmart stem cell technology.
Furthermore, Neuroscientific said previous clinical data showed StemSmart was effective in preventing graft-versus-host disease (GvHD), a common complication of bone-marrow transplants.
A phase I clinical trial in adults with steroid-refractory GVHD, and a series of children treated on compassionate grounds for steroid-refractory GVHD found the majority of adults and children responded to StemSmartTM with a complete or partial resolution of symptoms and improved survival.
Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) rose 15.7% in June after a series of positive announcements including positive topline data from two trials.
Its diagnostic phase II trial DISCO confirmed that Cu-SARTATE was safe and highly effective compared to standard-of-care imaging at detecting lesions in patients with neuroendocrine tumours.
Topline results from Clarity's Phase II SABRE trial showed that Cu-SAR-Bombesin was safe, well tolerated, and effective at detecting prostate cancer in patients with biochemical recurrence who had negative or unclear results on standard scans, including PSMA PET.
Neurizon Therapeutics (ASX:NUZ) rose 14.8% with a series of positive announcements including positive trial results for its lead drug candidate NUZ-001.
Preclinical data demonstrated significant neuroprotective effects of NUZ-001 and its active metabolite NUZ-001 Sulfone, in a zebrafish model of Huntington's disease.
Neurizon also reported encouraging new rodent preclinical pharmacokinetic (PK) data for NUZ-001 and NUZ-001 Sulfone, showing it effectively crosses the blood-brain barrier.
The ability of therapeutics to access the central nervous system remains a major barrier in treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis, the most common form of motor neurone disease, for which the company is focused.
At Stockhead, we tell it like it is. While Neurizon Therapeutics is a Stockhead advertiser, the company did not sponsor this article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Advertiser
an hour ago
- The Advertiser
Stocks dip, dollar slumps as Trump deal deadline looms
Stocks have slipped despite record highs for Wall Street overnight as US President Donald Trump's deadline for trade deals looms. The dollar retraced some of Thursday's gains with US markets already shut for the holiday-shortened week as traders considered the impact of the sweeping spending bill that Trump is expected to sign into law later in the day. The pan-European STOXX 600 index fell 0.6 per cent on Friday, driven in part by losses on spirits makers such as Pernod Ricard and Remy Cointreau after China said it would impose duties of up to 34.9 per cent on brandy from the European Union starting July 5. US S&P 500 futures edged down 0.5 per cent following a 0.8 per cent overnight advance for the cash index to a fresh record closing peak. Wall Street is closed on Friday for the Independence Day holiday. Trump said Washington would start sending letters to countries on Friday specifying what tariff rates they would face on exports to the United States, a clear shift from earlier pledges to strike scores of individual deals before a July 9 deadline when tariffs could rise sharply. Investors were "now just waiting for July 9", said Tony Sycamore, an analyst at IG, with the market's lack of optimism for trade deals responsible for some of the equity weakness in export-reliant Asia, particularly Japan and South Korea. At the same time, Thursday's jobs data showed "the US economy is holding together better than most people expected, which suggests to me that markets can easily continue to do better" from here, Sycamore said. Investors cheered the surprisingly robust jobs report on Thursday, sending all three of the main US equity indexes climbing in a shortened session. Following the close, the House narrowly approved Trump's signature, 869-page bill, which would add $US3.4 trillion ($A5.2 trillion) to the nation's $US36.2 trillion debt, according to the non-partisan Congressional Budget Office. Trump said he expected "a couple" more trade agreements after announcing a deal with Vietnam on Wednesday to add to framework agreements with China and Britain as the only successes so far. US Treasury Secretary Scott Bessent said earlier this week that a deal with India was close. However, agreements with Japan and South Korea, once touted by the White House as likely to be among the earliest to be announced, appear to have broken down. The US dollar rallied overnight, taking it up as much as 0.7 per cent versus a basket of major peers after the robust payrolls data saw traders take any expectations for a Federal Reserve interest rate cut in July off the table. It ended Thursday with a 0.4 per cent rise. On Friday, the US currency gave back a little of those gains, slumping 0.4 per cent to 144.31 yen and sliding 0.2 per cent to 0.7936 Swiss franc. The euro added 0.2 per cent to $US1.1773, while sterling held steady at $US1.3662. The US Treasury bond market is closed on Friday for the holiday, but 10-year yields rose 4.7 basis points to 4.34 per cent while the two-year yield jumped 9.3 bps to 3.882 per cent. Gold firmed 0.4 per cent to $US3,339 per ounce, on track for a weekly gain as investors again sought refuge in safe-haven assets due to concerns over the US's fiscal position and tariffs. Brent crude futures fell seven cents to $US68.73 a barrel, while US West Texas Intermediate crude was last seen flat at $US67.02. Stocks have slipped despite record highs for Wall Street overnight as US President Donald Trump's deadline for trade deals looms. The dollar retraced some of Thursday's gains with US markets already shut for the holiday-shortened week as traders considered the impact of the sweeping spending bill that Trump is expected to sign into law later in the day. The pan-European STOXX 600 index fell 0.6 per cent on Friday, driven in part by losses on spirits makers such as Pernod Ricard and Remy Cointreau after China said it would impose duties of up to 34.9 per cent on brandy from the European Union starting July 5. US S&P 500 futures edged down 0.5 per cent following a 0.8 per cent overnight advance for the cash index to a fresh record closing peak. Wall Street is closed on Friday for the Independence Day holiday. Trump said Washington would start sending letters to countries on Friday specifying what tariff rates they would face on exports to the United States, a clear shift from earlier pledges to strike scores of individual deals before a July 9 deadline when tariffs could rise sharply. Investors were "now just waiting for July 9", said Tony Sycamore, an analyst at IG, with the market's lack of optimism for trade deals responsible for some of the equity weakness in export-reliant Asia, particularly Japan and South Korea. At the same time, Thursday's jobs data showed "the US economy is holding together better than most people expected, which suggests to me that markets can easily continue to do better" from here, Sycamore said. Investors cheered the surprisingly robust jobs report on Thursday, sending all three of the main US equity indexes climbing in a shortened session. Following the close, the House narrowly approved Trump's signature, 869-page bill, which would add $US3.4 trillion ($A5.2 trillion) to the nation's $US36.2 trillion debt, according to the non-partisan Congressional Budget Office. Trump said he expected "a couple" more trade agreements after announcing a deal with Vietnam on Wednesday to add to framework agreements with China and Britain as the only successes so far. US Treasury Secretary Scott Bessent said earlier this week that a deal with India was close. However, agreements with Japan and South Korea, once touted by the White House as likely to be among the earliest to be announced, appear to have broken down. The US dollar rallied overnight, taking it up as much as 0.7 per cent versus a basket of major peers after the robust payrolls data saw traders take any expectations for a Federal Reserve interest rate cut in July off the table. It ended Thursday with a 0.4 per cent rise. On Friday, the US currency gave back a little of those gains, slumping 0.4 per cent to 144.31 yen and sliding 0.2 per cent to 0.7936 Swiss franc. The euro added 0.2 per cent to $US1.1773, while sterling held steady at $US1.3662. The US Treasury bond market is closed on Friday for the holiday, but 10-year yields rose 4.7 basis points to 4.34 per cent while the two-year yield jumped 9.3 bps to 3.882 per cent. Gold firmed 0.4 per cent to $US3,339 per ounce, on track for a weekly gain as investors again sought refuge in safe-haven assets due to concerns over the US's fiscal position and tariffs. Brent crude futures fell seven cents to $US68.73 a barrel, while US West Texas Intermediate crude was last seen flat at $US67.02. Stocks have slipped despite record highs for Wall Street overnight as US President Donald Trump's deadline for trade deals looms. The dollar retraced some of Thursday's gains with US markets already shut for the holiday-shortened week as traders considered the impact of the sweeping spending bill that Trump is expected to sign into law later in the day. The pan-European STOXX 600 index fell 0.6 per cent on Friday, driven in part by losses on spirits makers such as Pernod Ricard and Remy Cointreau after China said it would impose duties of up to 34.9 per cent on brandy from the European Union starting July 5. US S&P 500 futures edged down 0.5 per cent following a 0.8 per cent overnight advance for the cash index to a fresh record closing peak. Wall Street is closed on Friday for the Independence Day holiday. Trump said Washington would start sending letters to countries on Friday specifying what tariff rates they would face on exports to the United States, a clear shift from earlier pledges to strike scores of individual deals before a July 9 deadline when tariffs could rise sharply. Investors were "now just waiting for July 9", said Tony Sycamore, an analyst at IG, with the market's lack of optimism for trade deals responsible for some of the equity weakness in export-reliant Asia, particularly Japan and South Korea. At the same time, Thursday's jobs data showed "the US economy is holding together better than most people expected, which suggests to me that markets can easily continue to do better" from here, Sycamore said. Investors cheered the surprisingly robust jobs report on Thursday, sending all three of the main US equity indexes climbing in a shortened session. Following the close, the House narrowly approved Trump's signature, 869-page bill, which would add $US3.4 trillion ($A5.2 trillion) to the nation's $US36.2 trillion debt, according to the non-partisan Congressional Budget Office. Trump said he expected "a couple" more trade agreements after announcing a deal with Vietnam on Wednesday to add to framework agreements with China and Britain as the only successes so far. US Treasury Secretary Scott Bessent said earlier this week that a deal with India was close. However, agreements with Japan and South Korea, once touted by the White House as likely to be among the earliest to be announced, appear to have broken down. The US dollar rallied overnight, taking it up as much as 0.7 per cent versus a basket of major peers after the robust payrolls data saw traders take any expectations for a Federal Reserve interest rate cut in July off the table. It ended Thursday with a 0.4 per cent rise. On Friday, the US currency gave back a little of those gains, slumping 0.4 per cent to 144.31 yen and sliding 0.2 per cent to 0.7936 Swiss franc. The euro added 0.2 per cent to $US1.1773, while sterling held steady at $US1.3662. The US Treasury bond market is closed on Friday for the holiday, but 10-year yields rose 4.7 basis points to 4.34 per cent while the two-year yield jumped 9.3 bps to 3.882 per cent. Gold firmed 0.4 per cent to $US3,339 per ounce, on track for a weekly gain as investors again sought refuge in safe-haven assets due to concerns over the US's fiscal position and tariffs. Brent crude futures fell seven cents to $US68.73 a barrel, while US West Texas Intermediate crude was last seen flat at $US67.02. Stocks have slipped despite record highs for Wall Street overnight as US President Donald Trump's deadline for trade deals looms. The dollar retraced some of Thursday's gains with US markets already shut for the holiday-shortened week as traders considered the impact of the sweeping spending bill that Trump is expected to sign into law later in the day. The pan-European STOXX 600 index fell 0.6 per cent on Friday, driven in part by losses on spirits makers such as Pernod Ricard and Remy Cointreau after China said it would impose duties of up to 34.9 per cent on brandy from the European Union starting July 5. US S&P 500 futures edged down 0.5 per cent following a 0.8 per cent overnight advance for the cash index to a fresh record closing peak. Wall Street is closed on Friday for the Independence Day holiday. Trump said Washington would start sending letters to countries on Friday specifying what tariff rates they would face on exports to the United States, a clear shift from earlier pledges to strike scores of individual deals before a July 9 deadline when tariffs could rise sharply. Investors were "now just waiting for July 9", said Tony Sycamore, an analyst at IG, with the market's lack of optimism for trade deals responsible for some of the equity weakness in export-reliant Asia, particularly Japan and South Korea. At the same time, Thursday's jobs data showed "the US economy is holding together better than most people expected, which suggests to me that markets can easily continue to do better" from here, Sycamore said. Investors cheered the surprisingly robust jobs report on Thursday, sending all three of the main US equity indexes climbing in a shortened session. Following the close, the House narrowly approved Trump's signature, 869-page bill, which would add $US3.4 trillion ($A5.2 trillion) to the nation's $US36.2 trillion debt, according to the non-partisan Congressional Budget Office. Trump said he expected "a couple" more trade agreements after announcing a deal with Vietnam on Wednesday to add to framework agreements with China and Britain as the only successes so far. US Treasury Secretary Scott Bessent said earlier this week that a deal with India was close. However, agreements with Japan and South Korea, once touted by the White House as likely to be among the earliest to be announced, appear to have broken down. The US dollar rallied overnight, taking it up as much as 0.7 per cent versus a basket of major peers after the robust payrolls data saw traders take any expectations for a Federal Reserve interest rate cut in July off the table. It ended Thursday with a 0.4 per cent rise. On Friday, the US currency gave back a little of those gains, slumping 0.4 per cent to 144.31 yen and sliding 0.2 per cent to 0.7936 Swiss franc. The euro added 0.2 per cent to $US1.1773, while sterling held steady at $US1.3662. The US Treasury bond market is closed on Friday for the holiday, but 10-year yields rose 4.7 basis points to 4.34 per cent while the two-year yield jumped 9.3 bps to 3.882 per cent. Gold firmed 0.4 per cent to $US3,339 per ounce, on track for a weekly gain as investors again sought refuge in safe-haven assets due to concerns over the US's fiscal position and tariffs. Brent crude futures fell seven cents to $US68.73 a barrel, while US West Texas Intermediate crude was last seen flat at $US67.02.
ABC News
an hour ago
- ABC News
BTN Newsbreak 04/07/2025
CHEESE NIGHTMARES A new study has found that there might be some truth to the old tale that eating cheese before bed can give you nightmares. Yeah, turns out cheese and nightmares might be connected. See, a new study of about a thousand people in Canada found that for some people, eating dairy like cheese before bed worsened their sleep and made them have strange dreams or nightmares, especially if they were lactose intolerant! So, why? Well, at night our bodies are designed to put all our energy into sleeping, not digesting food, and experts say if we eat heavy stuff like desserts, sweets, and yes, cheese, before bed, it can make it harder to sleep. So, the big question is, can I still have Brie before bed? Well, experts say steering clear of heavy food two hours before bed is usually a good idea, and if you're craving a late-night snack, keep it light. BIG BEAUTIFUL BILL It looks like U.S President Donald Trump's Big Beautiful Bill is going ahead. The bill only just passed last night, with a tight 218 to 214 vote in the U.S House of Representatives. The bill aims to deliver tax cuts, which Republicans say will improve economic growth, and also fund the President's immigration crackdown. Some aren't happy with the bill and say it'll add trillions of dollars to the country's debt and cut important healthcare programs. But the President is optimistic and will sign the bill into law on the 4th of July. SUNSCREEN TESTING Now, you might remember a few weeks ago we told you about a sunscreen rating controversy, after consumer advocacy group CHOICE released this report, which found many Aussie sunscreens weren't living up to their advertised SPF rating. Since then, the brands behind the sunscreens have come out with their original test results showing their compliance. But an ABC investigation found that at least eight of those tests were done by the same overseas lab, Princeton Consumer Research, leading some industry experts to raise questions about the lab's accuracy and testing methods. The lab says that their testing process isn't a problem, while Australian regulators continue to investigate the findings. WHAT MAKES YOU COOL? Now, here's something pretty cool: scientists have been trying to figure out what makes cool people cool. Yeah, "cool" is an expression we use all the time. Even in other languages, they use the same word, "c'est cool". But are we all talking about the same thing? It's been hard to know until now. These researchers got almost 6000 participants across 13 countries, including Australia, to think about someone they personally know, who they think is cool, and to rate that person on 15 different personality traits. It turns out, all around the world, cool people are thought of as those who break rules, seek new experiences, and challenge authority. Then they wanted to test whether "cool" really just means the same as "good", but when participants were asked to think of a good person, the results were pretty different. Good people were described as being calm, following social expectations, and caring for other people. But the researchers also point out that staying authentic is an important part of being cool. HOT DOG WEIGH-IN First up, to the U.S, where competitors are gearing up for the big event, and this year is set to be a banger, no pun intended, as hot-dog-eating world record holder Joey Chestnut returns to the game! HUMBOLDT PENGUIN COMPETITION Now, to Chester Zoo in the UK, where this batch of 10 baby Humboldt penguins have just been named. Among the celestially inspired names are Ursa, Quasar, Orion, and Xena. But 2 babies don't yet have names, so the zoo has asked for suggestions from the public to help name them. HIGH HEEL RACE And finally to Spain where the 26th annual high heel race saw runners hurtling down this cobblestone street in Madrid, in various states of comfort. Is that duct tape? This year's winner took home 350 euro, or about 600 bucks in prize money.
SBS Australia
an hour ago
- SBS Australia
To buy, or to rent? How housing affordability stacks up across the states
To buy, or to rent? How housing affordability stacks up across the states Published 4 July 2025, 8:16 am It's an age old question: is it cheaper to buy or rent? A new report by property group Domain has revealed that servicing a mortgage on a house is cheaper in 6 per cent of suburbs around the country. For units, it's almost 23 per cent. But in Perth, nearly 83 per cent of apartments are cheaper to buy than rent. And while that may be a win for buyers, it highlights the struggles for those in the rental market.
